WO2013165898A3 - Compositions et procédés d'inhibition de résolvases - Google Patents

Compositions et procédés d'inhibition de résolvases Download PDF

Info

Publication number
WO2013165898A3
WO2013165898A3 PCT/US2013/038650 US2013038650W WO2013165898A3 WO 2013165898 A3 WO2013165898 A3 WO 2013165898A3 US 2013038650 W US2013038650 W US 2013038650W WO 2013165898 A3 WO2013165898 A3 WO 2013165898A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
resolvases
inhibiting
methods
inhibitors
Prior art date
Application number
PCT/US2013/038650
Other languages
English (en)
Other versions
WO2013165898A2 (fr
Inventor
Frederic D. Bushman
Young Hwang
Matt CULYBA
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Priority to US14/397,994 priority Critical patent/US20150094327A1/en
Publication of WO2013165898A2 publication Critical patent/WO2013165898A2/fr
Publication of WO2013165898A3 publication Critical patent/WO2013165898A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/065—Poxviridae, e.g. avipoxvirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une analyse à base de polarisation de fluorescence (FP) pour identifier des inhibiteurs du clivage d'ADN par une résolvase. L'invention concerne également des inhibiteurs de résolvase identifiés par l'analyse, ainsi que des dérivés et des analogues des inhibiteurs. Les compositions de l'invention peuvent être utilisées pour traiter une infection par un poxvirus.
PCT/US2013/038650 2012-05-01 2013-04-29 Compositions et procédés d'inhibition de résolvases WO2013165898A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/397,994 US20150094327A1 (en) 2012-05-01 2013-04-29 Compositions and methods for inhibiting resolvases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261640928P 2012-05-01 2012-05-01
US61/640,928 2012-05-01

Publications (2)

Publication Number Publication Date
WO2013165898A2 WO2013165898A2 (fr) 2013-11-07
WO2013165898A3 true WO2013165898A3 (fr) 2014-01-16

Family

ID=49515015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/038650 WO2013165898A2 (fr) 2012-05-01 2013-04-29 Compositions et procédés d'inhibition de résolvases

Country Status (1)

Country Link
WO (1) WO2013165898A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113874015B (zh) 2018-12-21 2024-05-24 细胞基因公司 Ripk2的噻吩并吡啶抑制剂
EP4146345A2 (fr) 2020-05-05 2023-03-15 Teon Therapeutics, Inc. Modulateurs de récepteur cannabinoïde de type 2 (cb2) et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071862A2 (fr) * 2004-12-30 2006-07-06 Takeda Pharmaceutical Company Limited Polymorphe de 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate
WO2009008906A2 (fr) * 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Composés thérapeutiques pour un blocage de la synthèse d'adn de poxvirus
US20100056516A1 (en) * 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071862A2 (fr) * 2004-12-30 2006-07-06 Takeda Pharmaceutical Company Limited Polymorphe de 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate
US20100056516A1 (en) * 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
WO2009008906A2 (fr) * 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Composés thérapeutiques pour un blocage de la synthèse d'adn de poxvirus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CULYBA, M ET AL.: "Bulged DNA Substrates For Identifying Poxvirus Resolvase Inhibitors.", NUCLEIC ACIDS RESEARCH, vol. 40, no. 16, 11 May 2012 (2012-05-11), pages E124, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articleslPMC34398751pdf/gks325.pdf> [retrieved on 20131030] *

Also Published As

Publication number Publication date
WO2013165898A2 (fr) 2013-11-07

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
WO2013163190A8 (fr) Inhibiteurs d&#39;adn pk
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
WO2014028589A3 (fr) Composés d&#39;acide benzoïque substitués par un 4-hétéroaryle à titre d&#39;inhibiteurs de rorgammat et leurs utilisations
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
WO2014153235A3 (fr) Inhibiteurs de l&#39;arginine méthyltransférase et utilisations de ceux-ci
WO2014153100A3 (fr) Inhibiteurs de l&#39;arginine méthyltransférase et utilisations de ceux-ci
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
EP4219465A3 (fr) Inhibiteurs de prmt5 et leurs utilisations
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu&#39;inhibiteurs de rorgammat et utilisations de ceux-ci
MX2015005015A (es) Inhibidores heteroarilo de pde4.
WO2011153157A3 (fr) Inhibiteurs benzoquinolone de vmat2
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
WO2013003298A3 (fr) Inhibiteurs de pde10
PH12015500211B1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
BR112014028991A2 (pt) triazóis como inibidores de kv3
WO2014155300A3 (fr) Dérivés pyrimidine aminée substitués en tant qu&#39;inhibiteurs de tak-1
PH12016501462A1 (en) Neprilysin inhibitors
WO2013057013A3 (fr) Dérivés d&#39;alcools 1-phényl-2-pyridinylalkyliques utilisés comme inhibiteurs de phosphodiestérase
MX2015000980A (es) Inhibidores de aril lactama cinasa.
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
MX2014001604A (es) Compuestos de antranilamida y sus usos como plaguicidas.
AU2015292632B2 (en) Aldosterone synthase inhibitors
MX2014001510A (es) Compuestos de antranilamida y sus usos como plaguicidas.
WO2016164295A3 (fr) Pyridines fusionnées en tant qu&#39;inhibiteurs de kinase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13784316

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14397994

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 13784316

Country of ref document: EP

Kind code of ref document: A2